This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Find Stocks Under $10 to Buy Amid Coronavirus Economic Reopening
by Benjamin Rains
We screened for strong 'cheap' stocks that are trading under $10 a share that investors might want to buy as the market rally continues...
Frontline (FRO) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Frontline (FRO) delivered earnings and revenue surprises of -1.09% and -3.54%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Frontline (FRO) to Report Q1 Earnings: What's in the Offing?
by Maharathi Basu
Frontline's (FRO) performance in Q1 is expected to have been affected by the coronavirus-induced supply-chain disruptions.
Should Value Investors Buy Frontline (FRO) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Frontline (FRO) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Frontline (FRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top Ranked Value Stocks to Buy for May 12th
by Zacks Equity Research
Here are four stocks with buy rank and strong value characteristics for investors to consider today, May 12th
Top Ranked Income Stocks to Buy for May 12th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, May 12th
Top Ranked Income Stocks to Buy for May 7th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, May 7th
Frontline (FRO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Frontline (FRO) closed at $9.36, marking a +0.97% move from the previous day.
Top Ranked Value Stocks to Buy for April 30th
by Zacks Equity Research
Here are four stocks with buy rank and strong value characteristics for investors to consider today, April 30th
Top Ranked Income Stocks to Buy for April 29th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, April 29th
GasLog Partners (GLOP) Catches Eye: Stock Jumps 5.8%
by Zacks Equity Research
GasLog Partners (GLOP) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Winning ETF Strategies to Counter Epic Oil Rout
by Sanghamitra Saha
These ETF strategies should be helpful for investors amid an energy market rout.
Oil Goes Negative, Tankers to Get a Boost: 3 Stocks to Gain
by Kaibalya Pravo Dey
The May crude futures contract - which expires today - witnesses massive abandonment from traders, who are moving on to the June contract.
4 Energy ETF Areas Better Positioned Amid Negative Oil
by Sanghamitra Saha
These energy ETF areas gained/lost little on the historic day when oil futures turned negative.
4 Investing Areas to Win From Negative Turn in Oil
by Sanghamitra Saha
As WTI crude's May futures turn negative, investors may find these investing areas lucrative.
Top Ranked Income Stocks to Buy for April 9th
by Zacks Equity Research
Here are four stocks with buy rank and strong income characteristics for investors to consider today, April 9th
Frontline (FRO) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Frontline (FRO) closed the most recent trading day at $7.99, moving -1.6% from the previous trading session.
The Zacks Analyst Blog Highlights: DHT, Summit Therapeutics, Sharps Compliance, Frontline and Kala Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: DHT, Summit Therapeutics, Sharps Compliance, Frontline and Kala Pharmaceuticals
Headwinds Swarm Expeditors (EXPD): Time to Dodge the Stock?
by Zacks Equity Research
Expeditors (EXPD) Q1 performance is likely to have been dampened by draining volumes due to the coronavirus outbreak.
5 Stocks Up on Signs of Slowdown in Coronavirus Cases
by Zacks Equity Research
Coronavirus shows signs of slowdown in the United States and some other countries. While investors look for positive developments in the stock market, here are five must-buy stocks poised to grow.
Analyzing Coronavirus-Hit US Economy on World Health Day: 6 Picks
by Sweta Killa
Let us examine the health of the U.S. economy this World Health Day amid the ongoing COVID-19 crisis and bring to investors notice some solid picks for a robust investment portfolio.
Implied Volatility Surging for Frontline (FRO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Frontline (FRO) stock based on the movements in the options market lately.
Top Ranked Momentum Stocks to Buy for April 6th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 6th
Prepare for 'Painful Two Weeks' With 5 ETF & Stock Strategies
by Sanghamitra Saha
Trump warns about worsening coronavirus situation the coming two weeks. This is how you can play the situation.